HUTCHMED (China) Ltd
HKEX:13
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
19.16
34.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HUTCHMED (China) Ltd stock under the Base Case scenario is 21.49 HKD. Compared to the current market price of 27.3 HKD, HUTCHMED (China) Ltd is Overvalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
HUTCHMED (China) Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HUTCHMED (China) Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
HUTCHMED (China) Ltd
Balance Sheet Decomposition
HUTCHMED (China) Ltd
Current Assets | 1B |
Cash & Short-Term Investments | 802.5m |
Receivables | 192.3m |
Other Current Assets | 53.5m |
Non-Current Assets | 212.6m |
Long-Term Investments | 80.5m |
PP&E | 94.8m |
Other Non-Current Assets | 37.3m |
Current Liabilities | 373.3m |
Accounts Payable | 43.4m |
Accrued Liabilities | 228.2m |
Short-Term Debt | 26.5m |
Other Current Liabilities | 75.2m |
Non-Current Liabilities | 147.5m |
Long-Term Debt | 55.6m |
Other Non-Current Liabilities | 91.9m |
Earnings Waterfall
HUTCHMED (China) Ltd
Revenue
|
610.8m
USD
|
Cost of Revenue
|
-356.3m
USD
|
Gross Profit
|
254.5m
USD
|
Operating Expenses
|
-375.3m
USD
|
Operating Income
|
-120.8m
USD
|
Other Expenses
|
78.8m
USD
|
Net Income
|
-42m
USD
|
Free Cash Flow Analysis
HUTCHMED (China) Ltd
USD | |
Free Cash Flow | USD |
In the first half of 2023, the company reported a 164% surge in revenue to over $530 million, mainly from upfront income from Takeda, while oncology product sales grew by 35%. Net profit rebounded from a $163 million loss to a $168 million gain. They're on track to achieve full-year revenue of $450 million to $550 million and aim for profitability by 2025. The fruquintinib U.S. NDA received priority review with potential approval by late 2023, and in-market sales of their novel products grew 16% to $101 million. With a strong cash balance of $850 million and reduced R&D expenditures, the company has streamlined operations towards sustained growth and anticipates at least 6 new compounds launched in China by 2025.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
HUTCHMED (China) Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
HUTCHMED (China) Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
HUTCHMED (China) Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
HUTCHMED (China) Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
HUTCHMED (China) Ltd
According to Wall Street analysts, the average 1-year price target for HUTCHMED (China) Ltd is 40.65 HKD with a low forecast of 27.42 HKD and a high forecast of 53.9 HKD.
Dividends
Current shareholder yield for HUTCHMED (China) Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Contact
IPO
Employees
Officers
The intrinsic value of one HUTCHMED (China) Ltd stock under the Base Case scenario is 21.49 HKD.
Compared to the current market price of 27.3 HKD, HUTCHMED (China) Ltd is Overvalued by 21%.